Showing 21-30 of 77 results for "".
- EADV News: Almirall’s Ilumetri Improves Well-being of Pso Patients and Their Familieshttps://practicaldermatology.com/news/eadv-news-almiralls-ilumetri-improves-well-being-of-pso-patients-and-their-families/2462056/Ilumetri (tildrakizumab) significantly improves the well-being of psoriasis patients and their relatives, according to new data presented at the European Association of Dermatology and Venereology Congress 2023. Interim data from the POSITIVE study showed that tildrakizumab significantly improved …
- MTX vs. CsA in AD: Which Is Best for Kids?https://practicaldermatology.com/news/mtx-vs-csa-in-ad-which-is-best-for-kids/2462008/Methotrexate bested cyclosporine in children with severe atopic dermatitis, a new study shows. While new systemic therapies for AD are being introduced, researchers want to establish a gold standard for treatment with the conventional systemic therapies like methotrexate and cyclosporine is needed…
- AD News: Lebrikizumab Clears Hurdle in EUhttps://practicaldermatology.com/news/ad-news-lebrikizumab-clears-hurdle-in-eu/2462005/The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Almirall's EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients aged 12 and older with a body weight of at least 40 kg who have moderate-to-severe …
- CeraVe Launches New #ClearItUpLikeADerm Campaignhttps://practicaldermatology.com/news/cerave-launches-new-clearituplikeaderm-campaign/2461996/CeraVe is launching its new Clear It Up Like a Derm campaign to educate consumers on preventing and treating acne. With the help of Drs. Muneeb Shah, Mamina Turegano and Evan A. Rieder, as well as TikTok's Charli D'Amelio (@charlidamelio) and Zach King (@zachking), the CeraVe #ClearItUpLikeADerm …
- Biosimilar News: Samsung Bioepis, Sandoz to Develop SB17, a Proposed Stelara Biosimilar to Stelarahttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-sandoz-to-develop-sb17-a-proposed-stelara-biosimilar-to-stelara/2461991/Samsung Bioepis Co., Ltd. has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelara (ustekinumab). Samsung Bioepis will be responsible for development, regulatory registration and manufacture and supply of the product in the United States (US), Canada, …
- La Roche-Posay Is the Official Sunscreen of the US Open for the Second Yearhttps://practicaldermatology.com/news/la-roche-posay-is-the-official-sunscreen-of-the-us-open-for-the-second-year/2461941/La Roche-Posay is continuing its partnership as the exclusive Official Sunscreen Partner of the US Open for the second year in a row. At the 2022 US Open, La Roche-Posay provided access to board-certified dermatologists to educate on sun safety and distributed 300,000 free sunscreen samples. The …
- Skin Cancer-related Mutations Higher in the UK Than Singaporehttps://practicaldermatology.com/news/skin-cancer-related-mutations-higher-in-the-uk-than-singapore/2461909/People in the UK have facial skin that is far more DNA damaged from the sun than people in Singapore, explaining the far higher risk of developing basal and squamous cell carcinomas in the UK, new research suggests. When researchers from the Wellcome Sanger Institute and their collaborators at the…
- Research Closes in on the Genetic Factors Underlying HS Riskhttps://practicaldermatology.com/news/research-closes-in-on-the-genetic-factors-underlying-hs-risk/2461893/Researchers have identified genetic locations for increased risk of hidradenitis suppurativa (HS). “This discovery is highly relevant because these changes may effect nearby genes in a way that leads to improper development of hair follicles and predispose them to the rupture,” says study author …
- Biosimilar Update: FDA Accepts Dr. Reddy’s Proposed Rituximab Biosimilar Application for Reviewhttps://practicaldermatology.com/news/biosimilar-update-fda-accepts-dr-reddys-proposed-rituximab-biosimilar-application-for-review/2461859/Dr. Reddy’s Laboratories Ltd’s Biologics License Application (BLA) for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the U.S. Food and Drug Administration (FDA). This closely follows acceptance of its rituximab biosimilar data for review by the E…
- WCD News: Tildrakizumab Improves Wellbeing of PsO Patientshttps://practicaldermatology.com/news/wcd-news-tildrakizumab-improves-wellbeing-of-pso-patients/2461848/Ilumetri (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasis, according to research reported by Almirall, S.A. (ALM) at poster at the 25th World Congress of Dermatology in Singapore. Patients taking tildrakizumab achieved a wellbeing status sim…